Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Phathom Pharmaceuticals (PHAT) Cash from Financing Activities (2022 - 2025)

Historic Cash from Financing Activities for Phathom Pharmaceuticals (PHAT) over the last 4 years, with Q3 2025 value amounting to -$271000.0.

  • Phathom Pharmaceuticals' Cash from Financing Activities fell 10022.2% to -$271000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $25.9 million, marking a year-over-year decrease of 9298.79%. This contributed to the annual value of $182.8 million for FY2024, which is 5027.64% down from last year.
  • Phathom Pharmaceuticals' Cash from Financing Activities amounted to -$271000.0 in Q3 2025, which was down 10022.2% from $80000.0 recorded in Q2 2025.
  • Phathom Pharmaceuticals' Cash from Financing Activities' 5-year high stood at $212.0 million during Q4 2023, with a 5-year trough of -$271000.0 in Q3 2025.
  • Over the past 4 years, Phathom Pharmaceuticals' median Cash from Financing Activities value was $24.6 million (recorded in 2022), while the average stood at $52.3 million.
  • In the last 5 years, Phathom Pharmaceuticals' Cash from Financing Activities soared by 93880000.0% in 2024 and then tumbled by 10022.2% in 2025.
  • Phathom Pharmaceuticals' Cash from Financing Activities (Quarter) stood at $24.6 million in 2022, then soared by 761.9% to $212.0 million in 2023, then tumbled by 87.71% to $26.0 million in 2024, then tumbled by 101.04% to -$271000.0 in 2025.
  • Its Cash from Financing Activities was -$271000.0 in Q3 2025, compared to $80000.0 in Q2 2025 and $26.0 million in Q4 2024.